Eris Lifesciences · NSE: ERIS · BSE: 540596
Q4 FY21 results · Jan–Mar 2021
Eris Lifesciences reported revenue from operations of ₹278.21 crore (up 11.9% from Q4 FY20) and net profit of ₹68.25 crore (up 21.3% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 278.21 | 248.57 | +11.9% | 310.42 | −10.4% |
| Other income | 2.21 | (1.07) | Turned profit | 3.07 | −28.0% |
| Total income | 280.42 | 247.50 | +13.3% | 313.50 | −10.6% |
| Profit before tax | 84.73 | 61.50 | +37.8% | 99.30 | −14.7% |
| Net profit for the period | 68.25 | 56.27 | +21.3% | 90.15 | −24.3% |
| EPS, basic (₹) | 5.03 | 4.13 | +21.8% | 6.64 | −24.2% |
| Net margin (%) | 24.5 | 22.6 | 29.0 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 256.85 | 230.74 | +11.3% | 287.13 | −10.5% |
| Other income | 2.75 | (0.80) | Turned profit | 3.43 | −19.9% |
| Total income | 259.60 | 229.94 | +12.9% | 290.56 | −10.7% |
| Profit before tax | 86.43 | 59.22 | +46.0% | 97.37 | −11.2% |
| Net profit for the period | 69.35 | 55.11 | +25.8% | 88.63 | −21.8% |
| EPS, basic (₹) | 5.11 | 4.05 | +26.2% | 6.52 | −21.6% |
| Net margin (%) | 27.0 | 23.9 | 30.9 |
Consolidated
- Filed with BSE
- 14 May 2021, 11:00 IST
- Board meeting
- 13 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 May 2021, 11:00 IST
- Board meeting
- 13 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE